OxyContin Settlement: Judge Approves Purdue & Sackler Deal
- Here's a breakdown of the key points from the provided text regarding the Purdue Pharma settlement:
- * Company Restructuring: purdue Pharma will be renamed knoa Pharma and will have new leadership.
Here’s a breakdown of the key points from the provided text regarding the Purdue Pharma settlement:
* Company Restructuring: purdue Pharma will be renamed knoa Pharma and will have new leadership. Future profits will be dedicated too fighting the opioid crisis, potentially starting in spring 2026.
* Sackler Family Restrictions: Certain Sackler family members will be barred from involvement in companies selling opioids internationally and from having their names attached to institutions through donations. Their names have already been removed from some museums and universities.
* Document Clarity: Company documents, even those typically protected by lawyer-client privilege, will be made public.
* Financial Compensation:
* Individuals: Approximately $850 million will be allocated to individuals harmed by Purdue’s opioids, wiht over $100 million specifically for children born with opioid withdrawal symptoms. This money will be distributed next year.
* Governments: Governments will receive funds, but it will take up to 15 years for them to receive their full allocations.
* Unique Aspect: This settlement differs from others in that it does provide direct financial compensation to individuals harmed by Purdue’s products.